Glioma Market: Epidemiology, Therapies, Companies, DelveInsight | Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano

Glioma therapies, such as ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others, are expected to boost the Glioma Market in the upcoming years.

DelveInsight has launched a new report on "Glioma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Glioma market report @ https://www.delveinsight.com/report-store/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Glioma Market Report:

According to DelveInsight estimates, the United States held the largest glioma market in 2023, valued at around USD 650 million. The current standard treatments for glioma-including surgery, radiation, temozolomide, and maintenance therapy with temozolomide-are largely ineffective, with 95% of patients experiencing relapse.
In February 2025, the FDA accepted a new drug application for the accelerated approval of dordaviprone (ONC201; Chimerix) to treat recurrent H3 K27M-mutant diffuse glioma.
In January 2025, Chimerix submitted this NDA, requesting priority review with a target action date set for Q3 2025 under the PDUFA program. Dordaviprone has also been granted rare pediatric disease designation for this indication.
In 2023, the United States accounted for the largest share of glioma cases, representing about 40% of the total in the 7MM. Within the EU4 and the UK, Germany had the highest number of glioma cases, followed by France, while Spain reported the fewest cases.
FDA-approved therapies for glioma include OPTUNE (Novocure), AVASTIN (Genentech), TEMODAR (Merck), and the combination of TAFINLAR + MEKINIST (Novartis). The FDA approved the biosimilar bevacizumab-bvzr (ZIRABEV; Pfizer) in June 2019 for the same indications as AVASTIN. This was the second bevacizumab biosimilar approved in the U.S., following bevacizumab-awwb (MVASI; Amgen) in 2017. The introduction of these biosimilars is expected to reduce bevacizumab's market share due to lower therapy costs.
In October 2023, the FDA accepted the NDA for tovorafenib monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG), granting it Priority Review with a PDUFA date set for April 30, 2024.
The market is expected to grow significantly due to promising results from several developmental-stage products, such as AV-GBM-1, ITI-1000, LAM561, DCVax-L, INO-5401+, INO-9012 + LIBTAYO, SurVaxM, Enzastaurin Hydrochloride, VAL-083, temferon, DAY101, vorasidenib, and others.
While the recent label expansion of Novartis' TAFINLAR (dabrafenib) + MEKINIST (trametinib) to treat pediatric patients aged one year and older with low-grade glioma harboring the BRAF V600E mutation broadens commercial opportunities, the limited number of approved therapies for low-grade glioma highlights a significant opportunity for developing new treatments in this segment.
Key Glioma companies such as Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceutical, and others are evaluating new drugs for Glioma to improve the treatment landscape.
Promising Glioma therapies include ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.

Glioma Overview

Glioma is the most common type of central nervous system (CNS) tumor, originating from glial cells. These tumors are highly invasive, spreading extensively into surrounding brain tissue. Gliomas are generally classified into three main types based on the characteristics of their cells: astrocytomas, ependymomas, and oligodendrogliomas. They develop due to genetic mutations accumulating in glial stem or progenitor cells, causing uncontrolled cell growth. Gliomas are graded on a scale from I to IV, with glioblastoma (GBM, Grade IV) being the most aggressive and pilocytic astrocytomas (Grade I) being the least malignant. Common mutated genes associated with gliomas include tumor suppressors like TP53 and PTEN, growth-related genes like BRAF, and metabolism-related genes such as IDH1.

Glioma Market Outlook

Gliomas are classified into four grades based on their level of differentiation, with Grade I being the most differentiated and least aggressive, and Grade IV being the least differentiated and most malignant. Treating gliomas requires a large multidisciplinary team of medical experts and healthcare professionals due to the complexity of the disease. Treatment is challenging because some tumor cells may respond well to certain therapies while others remain unaffected. Consequently, glioma treatment often involves a combination of methods, such as surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional adjuvant therapies like chemotherapy or radiation after surgery.

The initial treatment step is surgery, which aims to diagnose, relieve brain pressure, and remove as much of the tumor as safely possible. The goal is to achieve a "maximum safe resection," removing the greatest tumor amount without causing permanent neurological damage.

From a commercial standpoint, there is greater focus on high-grade gliomas compared to low-grade gliomas, as patients with low-grade gliomas generally have longer survival. As a result, only a few drugs targeting low-grade gliomas are in late-stage development, with most in early-phase trials. In contrast, the glioblastoma (GBM) pipeline is robust, featuring multiple promising drugs in mid and late-stage development, yet to be launched. These drugs vary in their mechanisms of action and delivery methods. Notably, the emerging glioma market includes innovative gene therapies such as ofranergene obadenovec (VB-111) by VBL Therapeutics, alongside several vaccine and immunotherapy candidates like VBI-1901, AV-GBM-1, ITI-1000 (pp65 DC Vaccine), and tasadenoturev (DNX-2401) developed by companies including VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, all poised to significantly impact market dynamics in the coming years.

Discover how the Glioma market is rising in the coming years @ https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Glioma Marketed Drugs
AVASTIN: Genentech
TEMODAR (temozolomide): Merck

Glioma Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics
SurVaxM: MimiVax
Vorasidenib (AG-881): Servier
Tovorafenib (DAY101): Day One Biopharmaceuticals

Scope of the Glioma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Glioma Companies: Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceutical, and others
Glioma Therapies: ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.
Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
Glioma Market Dynamics: Glioma market drivers and Glioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Glioma Unmet Needs, KOL's views, Analyst's views, Glioma Market Access and Reimbursement

To know what's more in our Glioma report, visit https://www.delveinsight.com/report-store/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Glioma Market Report:
Glioma market report covers a descriptive overview and comprehensive insight of the Glioma Epidemiology and Glioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Glioma market report provides insights into the current and emerging therapies.
The Glioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Glioma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glioma market.

Got queries? Click here to know more about the Glioma market Landscape https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Glioma Patient Share (%) Overview at a Glance
5. Glioma Market Overview at a Glance
6. Glioma Disease Background and Overview
7. Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glioma
9. Glioma Current Treatment and Medical Practices
10. Unmet Needs
11. Glioma Emerging Therapies
12. Glioma Market Outlook
13. Country-Wise Glioma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Glioma Market Outlook 2034 https://www.delveinsight.com/report-store/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Glioma Pipeline Insights, DelveInsight

"Glioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glioma market. A detailed picture of the Glioma pipeline landscape is provided, which includes the disease overview and Glioma treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.